Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

2.640 +0.100 (+3.94%)
Streaming Delayed Price Updated: 11:00 AM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 64,637
Open 2.700
Bid (Size) 2.610 (600)
Ask (Size) 2.650 (100)
Prev. Close 2.540
Today's Range 2.600 - 2.735
52wk Range 1.110 - 5.744
Shares Outstanding 11,184,423
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches withZeta.ai Platform, Opens New Revenue Stream
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22
From Lantern Pharma Inc.
Via Business Wire

Performance

YTD
-15.1%
-15.1%
1 Month
+13.3%
+13.3%
3 Month
-24.8%
-24.8%
6 Month
-38.9%
-38.9%
1 Year
-24.4%
-24.4%

More News

Read More
Unusual volume stocks in Thursday's session ↗
Via Chartmill
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Host April 9 Investor Briefing Featuring Live Demo Of withZeta.ai Platform
Via Investor Brand Network
Topics Artificial Intelligence
MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Host April 9 Investor Briefing Featuring Live Demo Of withZeta.ai Platform
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor Conference
Via ACCESS Newswire
News headline image
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026
From Lantern Pharma Inc.
Via Business Wire
Which stocks have an unusual volume on Wednesday? ↗
Via Chartmill
BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Advances AI-Driven Oncology Pipeline With Multiple 2026 Milestones in View
Via Investor Brand Network
Topics Artificial Intelligence
Discover the top movers in Tuesday's pre-market session. ↗
Via Chartmill
News headline image
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
From Lantern Pharma Inc.
Via Business Wire
These stocks have an unusual volume in today's session ↗
Via Chartmill
News headline image
New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)
Via ACCESS Newswire
News headline image
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report
From Lantern Pharma Inc.
Via Business Wire
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives FDA Clearance For STAR-001 Pediatric CNS Cancer Trial
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001
From Lantern Pharma Inc.
Via Business Wire
News headline image
RedChip AI Investor Conference Replays Now Available Highlighting Companies Driving Innovation Across the AI Ecosystem
Via ACCESS Newswire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Schedules Fourth Quarter And Fiscal Year 2025 Results Webcast
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST
Via ACCESS Newswire
News headline image
RedChip Highlights Public Companies Advancing the Next Phase of AI Adoption at Virtual Investor Conference on March 19
Via ACCESS Newswire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) to Present AI-Driven Neuro-Oncology Strategy at Glioblastoma Summit
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026
From Lantern Pharma Inc.
Via Business Wire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Receives FDA Orphan Drug Designation For LP-284 In Soft Tissue Sarcomas
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
From Lantern Pharma Inc.
Via Business Wire

Frequently Asked Questions

Is Lantern Pharma Inc. - Common Stock publicly traded?
Yes, Lantern Pharma Inc. - Common Stock is publicly traded.
What exchange does Lantern Pharma Inc. - Common Stock trade on?
Lantern Pharma Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lantern Pharma Inc. - Common Stock?
The ticker symbol for Lantern Pharma Inc. - Common Stock is LTRN on the Nasdaq Stock Market
What is the current price of Lantern Pharma Inc. - Common Stock?
The current price of Lantern Pharma Inc. - Common Stock is 2.640
When was Lantern Pharma Inc. - Common Stock last traded?
The last trade of Lantern Pharma Inc. - Common Stock was at 04/17/26 11:00 AM ET
What is the market capitalization of Lantern Pharma Inc. - Common Stock?
The market capitalization of Lantern Pharma Inc. - Common Stock is 29.53M
How many shares of Lantern Pharma Inc. - Common Stock are outstanding?
Lantern Pharma Inc. - Common Stock has 30M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.